'It will take the combined efforts of sleep labs and connected home solutions like NightOwl to identify a significant portion of the hundreds of millions of people suffering from this disease that don't even know it.'Įctosense will operate within ResMed's Sleep and Respiratory Care business. 'ResMed has the global reach and passionate ambition to help increase patient access to Ectosense's proven diagnostic solution and a path to better sleep and overall health,' said Frederik Massie, chief technology officer and cofounder of Ectosense. We're excited to welcome Ectosense's life-changing team to the ResMed family.' 'Ectosense's clinically validated, consumer-friendly devices will enable us to help millions of people in many markets improve their sleep and overall health. 'In developing markets, we need to make sleep tests affordable, accessible and easy to use,' said Justin Leong, ResMed president of Asia and Latin America. 2 Digital health solutions help patients stay on sleep apnea therapy once they start (up to 87% are adherent on connected solutions). For millions of people, their best night's sleep must start with a diagnosis.'Īn estimated 936 million people worldwide have sleep apnea, 1 and over 80% remain undiagnosed. 'We believe Ectosense's digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. 'Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea,' said Jim Hollingshead, ResMed president of Sleep and Respiratory Care. ResMed has distributed NightOwl in Australia, New Zealand, and India since 2020 under the brand 'ResMed onesleeptest™,' and has been a minority investor in Ectosense since July 2020. OctoResMed today has completed the acquisition of Ectosense, a leader in cloud-connected home sleep test (HST) devices that can help millions of people with undiagnosed sleep apnea get the treatment they need - and raise general awareness of the disease.Įctosense's FDA-approved NightOwl™ is sold in the United States, Australia, New Zealand, India, and parts of Europe. With awareness of the condition and requests for home screenings on the rise, “it’s a very reasonable test to consider as an alternative for patients who are highly likely to have moderate to severe OSA” says Neeraj Kaplish, M.D., an assistant professor of neurology and the medical director of the Sleep Lab at the University of Michigan’s Sleep Disorders Center. “But for a lot of patients, it’s probably not the appropriate testing.”īelow, Kaplish explains a few pros and cons of home sleep apnea tests.Ectosense's NightOwl™ is a leading FDA-approved cloud-connected home sleep apnea test OSA is associated with increased risk of stroke and heart disease, among other medical conditions.ĭoctors, then, might recommend home testing or a formal sleep study to make sure people get the accurate diagnosis - and treatment - they need. It leads to oxygen shortages that, in turn, result in health outcomes far worse than simply noisy breathing and unrefreshing sleep. OSA is characterized by repeated obstructed or restricted breathing for periods of 10 seconds or longer, and it affects more than 25 million Americans. Home sleep apnea tests have given many people a convenient, more comfortable means of evaluation. But it also involves spending a night away from home hooked to a bevy of electrodes and machinery in a clinic bed. That’s still the most comprehensive assessment. In the past, obstructive sleep apnea (OSA) could only be diagnosed one way: through a sleep study, or polysomnography.

Nightowl sleep study